Dr. Francesca Klinger
2014 to date Assistant Professor of Histology, University of Rome Tor Vergata, Dept. Biomedicine and Prevention, Rome, Italy
2006 to date Researcher at University of Rome Tor Vergata Dep. Biomedicine and Prevention-Histology-Bio17
2004-2006 Post Doc contract at University of Rome Tor Vergata, Dep. Public Health and Cell Biology
2002-2004 Post Doc contract at the National Institute for Medical Research, Division of Developmental Genetics, London, UK; Cesare Serono Foundation Fellowship
1998 Degree with Honors in Biology, University of Rome Tor Vergata
Other Experience and Professional Memberships
Ad Hoc Reviewer for different journal with IF
2017 Reviewer for ESHRE Meeting abstract selection - section Embryology
2010 to date ESHRE (European Society for Human Reproduction and Embryology) Membership
2016 to date ISFP (International Society for Fertility Preservation) Membership
2016 to date SIERR (Società Italiana di Embriologia, Riproduzione e Ricerca) Membership
2017 Invited Speaker, 17th World Congress Academy Human Reproduction, Rome, Italy
2017 Invited Speaker, 1st Fertility Preservation in UK Meeting, Edinburgh, UK
6 Invitations as main speaker/discussant at National Congresses
Dr. Klinger has a broad background in reproductive and developmental biology, in histology, and stem cell biology, with a primary focus on investigating how chemotherapy treatment can impact on subsequent female fertility and ovarian function.
Dr. Klinger possesses expertise on handling and culture oocytes and ovarian follicles, culture of primordial germ cells and stem cells of different sources (embryonic, adult, induced), morphological, biochemical, histological and molecular biology techniques.
This expertise has allowed Dr Klinger to establish strong collaborations with national and international research groups. Three main research lines are currently followed in the laboratory: 1) Study of new mechanisms to protect the ovary from chemiotherapic treatments; 2) Effect of LH on damage induced in mouse ovarian somatic cells by chemotherapeutic drugs; 3) Reprogramming mesenchymal stem cells into PGCLCs in vitro.
These studies are funded by the European Society for Human Reproduction and Embryology, Merck Company and Convert Italia.